Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

78.88USD
20 May 2019
Change (% chg)

$0.16 (+0.20%)
Prev Close
$78.72
Open
$78.50
Day's High
$79.27
Day's Low
$78.26
Volume
2,912,918
Avg. Vol
3,443,541
52-wk High
$83.81
52-wk Low
$58.03

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $202,676.00
Shares Outstanding(Mil.): 2,574.65
Dividend: 0.55
Yield (%): 2.79

Financials

  MRK.N Industry Sector
P/E (TTM): 24.80 54.03 55.51
EPS (TTM): 3.17 -- --
ROI: 12.55 11.89 11.59
ROE: 27.44 13.19 16.33

Merck's Keytruda fails as monotherapy in breast cancer study

Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

20 May 2019

UPDATE 1-Merck's Keytruda fails as monotherapy in breast cancer study

May 20 Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

20 May 2019

Merck's Keytruda fails as monotherapy in breast cancer study

May 20 Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the treatment as a monotherapy in patients with an aggressive type of breast cancer.

20 May 2019

Supreme Court gives Merck another shot to avoid Fosamax lawsuits

WASHINGTON The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation.

20 May 2019

UPDATE 3-U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits

* Lower courts to revisit case using Supreme Court guidance (Recasts first paragraph, adds comment from Merck and plaintiffs, details from ruling)

20 May 2019

CPPIB buys partial Keytruda royalty interest from British charity LifeArc

Canada Pension Plan Investment Board said it had paid about $1.3 billion (£1.02 billion) for a part of British charity LifeArc's royalty interest from the sale of Merck & Co Inc's blockbuster cancer immunotherapy, Keytruda.

20 May 2019

CPPIB buys partial Keytruda royalty interest from British charity LifeArc

May 20 Canada Pension Plan Investment Board said it had paid about $1.3 billion for a part of British charity LifeArc's royalty interest from the sale of Merck & Co Inc's blockbuster cancer immunotherapy, Keytruda.

20 May 2019

Merck steps up U.S. measles vaccine production with increased demand

NEW YORK Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.

01 May 2019

Merck steps up U.S. measles vaccine production with increased demand

NEW YORK, May 1 Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country's biggest outbreak in 25 years.

01 May 2019

Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

30 Apr 2019

Earnings vs. Estimates